ScreenerHero

BCTX BriaCell Therapeutics Corp.

NAS · US · Healthcare · Biotechnology · briacell.com
4.000USD-0.50%Mkt Cap: 34.80M $P/E: —

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone

BriaCell Therapeutics (NASDAQ:BCTX) shares experienced a volatile session on Monday after the biotechnology company announced that its Bria-MEL+ melanoma vaccine candidate had reached an important genetic engineering milestone. The stock initially jumped 25% following the announcement before surrendering those gains later in the session, highlighting the market’s shifting reaction to the development-stage programme.

InvestorsHub
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?

In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for Bria-IMT, its investigational metastatic breast cancer therapy currently in a pivotal Phase 3 trial. This engagement highlights how CRA International’s specialized healthcare and market access expertise is being tapped early in the oncology commercialization process, underscoring its...

Simply Wall St.